Want to see HK:2393 full AI Analyst Report?
2393 Stock Chart & Stats
HK$0.10
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$0.10
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.05 - HK$0.20
Previous CloseN/A
Volume710.00K
Average Volume (3M)2.34M
Market Cap
HK$128.13M
Enterprise ValueHK$117.23M
Total Cash (Recent Filing)HK$234.51M
Total Debt (Recent Filing)HK$211.05M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding2,331,590,000
10 Day Avg. Volume1,184,000
30 Day Avg. Volume2,342,546
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.56
Price to Sales (P/S)0.14
P/FCF Ratio0.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Balance SheetRestoration of positive equity and materially lower leverage improves solvency and financial flexibility. This structural repair reduces refinancing and liquidity risk, enabling the company to withstand downturns, invest in service capacity or M&A, and prioritize deleveraging or strategic spending over the next 2–6 months.
Strong 2025 Cash GenerationA significant rebound in operating and free cash flow provides tangible, durable resources for debt reduction, working capital and reinvestment. Consistent cash conversion even amid accounting losses supports operational continuity and funds capex or platform expansion without immediate external financing.
Defensible Service PlatformA platform built on medical aesthetics and eye-care offers recurring, patient-driven demand and multiple revenue streams (services, procedures, products). This diversification across clinical services and product sales supports cross-selling, better utilization of clinical capacity, and structural demand resilience.
Bears Say
Sharp Revenue ContractionA pronounced top-line decline weakens scale economics and erodes ability to cover fixed clinic and staff costs. If revenue shrinkage persists, it can compress margins, limit reinvestment, and force pricing or service cuts that harm long-term market position and patient retention.
Volatile Profitability / Return To LossReversion to net losses and wide swings in margins indicate unstable earnings power. This unpredictability undermines sustainable ROE, complicates capital allocation, and reduces ability to fund growth internally. Persistent volatility raises execution risk for any multi-quarter recovery plan.
Historic Cash Flow VolatilityDespite a strong 2025, prior years showed negative or weak operating/free cash flow, signalling cyclicality. Such volatility risks liquidity pressure in downturns, makes planning capex or debt servicing harder, and reduces confidence that recent cash improvements will be durable.
Yestar Healthcare Holdings Co Ltd News
2393 FAQ
What was Yestar Healthcare Holdings Co Ltd’s price range in the past 12 months?
Yestar Healthcare Holdings Co Ltd lowest stock price was HK$0.05 and its highest was HK$0.20 in the past 12 months.
What is Yestar Healthcare Holdings Co Ltd’s market cap?
Yestar Healthcare Holdings Co Ltd’s market cap is HK$128.13M.
When is Yestar Healthcare Holdings Co Ltd’s upcoming earnings report date?
Yestar Healthcare Holdings Co Ltd’s upcoming earnings report date is Aug 27, 2026 which is in 53 days.
How were Yestar Healthcare Holdings Co Ltd’s earnings last quarter?
Yestar Healthcare Holdings Co Ltd released its earnings results on Mar 27, 2026. The company reported -HK$0.038 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.038.
Is Yestar Healthcare Holdings Co Ltd overvalued?
According to Wall Street analysts Yestar Healthcare Holdings Co Ltd’s price is currently Overvalued.
Does Yestar Healthcare Holdings Co Ltd pay dividends?
Yestar Healthcare Holdings Co Ltd pays a Annually dividend of HK$0.055 which represents an annual dividend yield of N/A. See more information on Yestar Healthcare Holdings Co Ltd dividends here
What is Yestar Healthcare Holdings Co Ltd’s EPS estimate?
Yestar Healthcare Holdings Co Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Yestar Healthcare Holdings Co Ltd have?
Yestar Healthcare Holdings Co Ltd has 2,331,590,000 shares outstanding.
What happened to Yestar Healthcare Holdings Co Ltd’s price movement after its last earnings report?
Yestar Healthcare Holdings Co Ltd reported an EPS of -HK$0.038 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.02%.
Which hedge fund is a major shareholder of Yestar Healthcare Holdings Co Ltd?
Currently, no hedge funds are holding shares in HK:2393
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Yestar Healthcare Holdings Co Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
44.31%
12-Months-Change
Fundamentals
Return on Equity
-17.70%
Trailing 12-Months
Asset Growth
-12.60%
Trailing 12-Months
Company Description
Yestar Healthcare Holdings Co Ltd
Yestar Healthcare Holdings Company Limited, an investment holding company, manufactures, distributes, and sells medical imaging products in Mainland China. The company operates in two segments, Imaging Printing Products, and Medical Products and Equipment. The Imaging Printing Products segment manufactures and sells color photographic paper and industrial NDT x-ray films and PWB films, as well as trades in imaging equipment. The Medical Products and Equipment segment manufactures and sells medical dry, medical wet, and dental films, as well as sells medical equipment and diagnostic reagents. The company also engages in the management of supply chain and service of freight transportation equipment, as well as development of biotechnology. The company was formerly known as Yestar International Holdings Company Limited and changed its name to Yestar Healthcare Holdings Company Limited in January 2017. Yestar Healthcare Holdings Company Limited was founded in 1971 and is headquartered in Shanghai, the People’s Republic of China.
Technical Analysis
Peijia Medical Ltd.
―
Acotec Scientific Holdings Limited
―
Vincent Medical Holdings Limited
―
Sisram Medical Ltd.
―
Venus Medtech (Hangzhou), Inc. Class H
―